HNSBF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of -213.29% compared to Hansa Biopharma AB's net margin of -25.62%. Hansa Biopharma AB's return on equity of -- beat BioArctic AB's return on equity of -23.03%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than BioArctic AB, analysts believe Hansa Biopharma AB is more attractive than BioArctic AB.

Hansa Biopharma AB has a beta of 0.486, which suggesting that the stock is 51.431% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $4.7M, which are smaller than BioArctic AB quarterly revenues of $7.4M. Hansa Biopharma AB's net income of -$10M is lower than BioArctic AB's net income of -$1.9M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while BioArctic AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 9.81x versus 107.08x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of -213.29% compared to Hansa Biopharma AB's net margin of 26.97%. Hansa Biopharma AB's return on equity of -- beat Camurus AB's return on equity of 11.41%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Camurus AB, analysts believe Hansa Biopharma AB is more attractive than Camurus AB.

Hansa Biopharma AB has a beta of 0.486, which suggesting that the stock is 51.431% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $4.7M, which are smaller than Camurus AB quarterly revenues of $46.2M. Hansa Biopharma AB's net income of -$10M is lower than Camurus AB's net income of $12.5M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Camurus AB's PE ratio is 119.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 9.81x versus 18.70x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Abliva AB has a net margin of -213.29% compared to Hansa Biopharma AB's net margin of --. Hansa Biopharma AB's return on equity of -- beat Abliva AB's return on equity of --.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Abliva AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Abliva AB, analysts believe Hansa Biopharma AB is more attractive than Abliva AB.

Hansa Biopharma AB has a beta of 0.486, which suggesting that the stock is 51.431% less volatile than S&P 500. In comparison Abliva AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abliva AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Abliva AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $4.7M, which are larger than Abliva AB quarterly revenues of --. Hansa Biopharma AB's net income of -$10M is lower than Abliva AB's net income of -$1.9M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Abliva AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 9.81x versus -- for Abliva AB. Usually stocks with elevated PS ratios are considered overvalued.

Oncopeptides AB has a net margin of -213.29% compared to Hansa Biopharma AB's net margin of --. Hansa Biopharma AB's return on equity of -- beat Oncopeptides AB's return on equity of --.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncopeptides AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Oncopeptides AB, analysts believe Hansa Biopharma AB is more attractive than Oncopeptides AB.

Hansa Biopharma AB has a beta of 0.486, which suggesting that the stock is 51.431% less volatile than S&P 500. In comparison Oncopeptides AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncopeptides AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Oncopeptides AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $4.7M, which are larger than Oncopeptides AB quarterly revenues of --. Hansa Biopharma AB's net income of -$10M is higher than Oncopeptides AB's net income of --. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Oncopeptides AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 9.81x versus 8.28x for Oncopeptides AB. Usually stocks with elevated PS ratios are considered overvalued.